Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of swelling in the deeper layers of the skin and mucous membranes. Unlike many forms of allergic angioedema, HAE typically occurs without hives or itching and is commonly associated with changes involving the bradykinin pathway. Swelling may affect the hands, feet, face, abdomen, genitals, or upper airway, and the pattern can vary between individuals. Understanding hereditary angioedema symptoms and characteristics can help explain how the condition differs from other causes of recurrent swelling.
The condition is associated with several biological and genetic mechanisms, with the most established forms involving deficiency or dysfunction of C1 inhibitor, a protein that helps regulate parts of the immune and inflammatory systems. HAE can also occur with normal C1 inhibitor levels and function, and several genetic variants have been associated with these forms. Because symptoms can resemble other disorders, hereditary angioedema diagnosis generally involves clinical assessment together with laboratory testing and, in selected cases, genetic evaluation.
Hereditary angioedema is an inherited disorder in which episodes of localized swelling occur because of abnormal regulation of pathways involved in inflammation and blood-vessel permeability. Bradykinin is an important mediator in many forms of HAE and can increase vascular permeability, allowing fluid to move into surrounding tissues. This produces the characteristic swelling associated with the condition. The swelling generally affects deeper tissues rather than producing the superficial wheals commonly associated with histamine-mediated allergic reactions.
Hereditary angioedema symptoms can differ considerably in frequency, location, and severity. Common manifestations include swelling of the hands, feet, arms, legs, face, lips, or genital area. Abdominal involvement can cause significant pain, nausea, vomiting, or diarrhea when swelling affects the intestinal wall. Swelling of the upper airway, including the throat or laryngeal area, is a particularly important clinical manifestation because it can interfere with breathing.
A key feature among hereditary angioedema characteristics is the absence of typical hives during many attacks. Swelling may develop gradually and can persist for several days before resolving. Some individuals experience warning symptoms before visible swelling, although these signs are not present in every episode. The unpredictable nature of hereditary angioedema attacks means that symptoms can vary even within the same person.
The most established hereditary angioedema causes involve genetic changes affecting the SERPING1 gene, which provides instructions for producing C1 inhibitor. C1 inhibitor helps regulate several plasma protein systems, including pathways involved in complement and contact activation. When C1 inhibitor is insufficient or does not function properly, regulation of these pathways can become abnormal, contributing to increased bradykinin production and tissue swelling.
HAE is generally inherited in an autosomal dominant pattern, meaning a disease-causing variant can be passed from an affected parent to a child. However, some people develop the condition because of a new genetic change rather than an identified family history. Consequently, the absence of known affected relatives does not by itself exclude HAE. Genetic counseling and appropriate testing can be considered when hereditary disease is suspected.
The traditional classification identifies type 1 HAE as a condition involving reduced amounts of functional C1 inhibitor and type 2 HAE as a condition in which C1 inhibitor is present but functions abnormally. Current guidelines group these forms under HAE with C1 inhibitor deficiency, or HAE-C1-INH, because they share important biological and management characteristics.
Another category is hereditary angioedema with normal C1 inhibitor, often referred to as HAE-nC1-INH. Several genetic variants have been associated with this group, including variants involving F12 and other genes. Some cases do not currently have an identified genetic cause. These forms can present with recurrent swelling despite laboratory measurements of C1 inhibitor concentration and function being within expected ranges, which can make diagnosis more complex.
Hereditary angioedema risk factors primarily relate to genetics and family history rather than lifestyle choices. Having a parent or close biological relative with confirmed HAE increases the likelihood of inheriting the condition. A personal history of recurrent swelling without hives, particularly when episodes involve the abdomen or upper airway, can also increase clinical suspicion. Early onset of recurrent episodes may provide another clue, although symptoms can begin at different ages.
Certain situations can precede or contribute to attacks in susceptible individuals. Physical trauma, medical or dental procedures, hormonal changes, infections, and psychological or physical stress have been reported as potential triggers. However, triggers vary between individuals, and an attack can occur without an identifiable precipitating factor. For this reason, the presence or absence of a known trigger does not establish or exclude HAE.
Hereditary angioedema diagnosis begins with recognition of the characteristic clinical pattern and consideration of alternative causes of angioedema. In suspected HAE with C1 inhibitor deficiency, laboratory assessment commonly includes complement component C4, C1 inhibitor protein concentration, and C1 inhibitor functional activity. Abnormal findings may need confirmation through repeat testing, particularly when the clinical presentation and laboratory results do not correspond.
The diagnostic process can be more complicated for HAE with normal C1 inhibitor. In these cases, physicians may consider the patient's clinical history, family history, response to previous treatments, laboratory findings, and available genetic testing. Specialized evaluation may be appropriate because other inherited, acquired, medication-related, and allergic causes of recurrent angioedema can produce overlapping symptoms.
Hereditary angioedema attacks are episodes of localized swelling that can affect different parts of the body at different times. Skin swelling commonly occurs in the extremities or face, while abdominal attacks can cause pain and gastrointestinal symptoms. Upper-airway attacks require particular attention because swelling in the throat or larynx can compromise the airway. The clinical severity and frequency of attacks vary substantially among individuals.
Because airway involvement can become serious, people with diagnosed HAE generally require an individualized management plan that addresses acute episodes and longer-term disease control. Medical evaluation is particularly important when swelling affects breathing or swallowing.
Hereditary angioedema treatment options are selected according to the individual's disease type, attack pattern, medical circumstances, treatment availability, and clinical guidance. Current management generally includes treatment intended for acute attacks, short-term preventive treatment in selected situations, and long-term preventive therapy when appropriate. International guidelines emphasize individualized care and access to suitable on-demand treatment for confirmed HAE.
For acute attacks, therapies may include C1 inhibitor replacement products and medicines that target the kallikrein-bradykinin pathway. Treatment selection depends on the specific product, regulatory availability, patient characteristics, and physician recommendations. Long-term preventive approaches can also involve different targeted medicines, while older therapies such as attenuated androgens may be considered differently because of their adverse-effect profiles. Treatment decisions should therefore be made with a qualified healthcare professional familiar with HAE.
In India and other settings where access to specialized diagnostics or medicines can vary, treatment approaches may also be influenced by availability and healthcare resources. Indian-subcontinent guidance has highlighted the importance of diagnosis, access to appropriate C1 inhibitor therapy, and individualized management in resource-constrained settings.
Hereditary angioedema is a lifelong genetic disorder with recognizable clinical patterns but considerable variation between individuals. Recurrent swelling without hives, abdominal symptoms, family history, and episodes involving the upper airway are among the features that can prompt evaluation. Laboratory testing helps distinguish major forms of HAE, while newer genetic information continues to refine classification. Understanding hereditary angioedema symptoms, causes, types, risk factors, diagnostic methods, and treatment options provides a foundation for recognizing the condition and discussing appropriate evaluation and management with a healthcare professional.